Business Context and Reporting Period
This Form 8-K Current Report is filed by aTyr Pharma, Inc. (Ticker: LIFE) on June 28, 2019. The filing reports a material modification to the rights of security holders and amendments to the Company's Articles of Incorporation. The Company is incorporated in Delaware and its common stock trades on the NASDAQ Capital Market.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and capital structure changes.
Material Changes Versus Prior Period
The primary material change reported is the implementation of a 1-for-14 reverse stock split of the Company's common stock, effective at 5:00 p.m. Eastern Time on June 28, 2019. Key structural changes include:
- Outstanding Shares: Reduced from approximately 49.4 million to approximately 3.5 million.
- Authorized Shares: Reduced from 150.0 million to 10.7 million.
- Preferred Stock Conversion: Shares of Series X Preferred Stock issuable upon conversion reduced from 8.2 million to 0.6 million.
- Equity Awards: Proportionate adjustments made to exercise prices and share counts for outstanding stock options, restricted stock units, and warrants.
- Trading Status: Common stock began trading on a split-adjusted basis on July 1, 2019, under the ticker symbol "LIFE" with a new CUSIP number (002120 202).
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future operations, or specific risk factors beyond the standard implications of a reverse stock split. The Company noted that no fractional shares will be issued; instead, stockholders entitled to fractional shares will receive a rounding up to the nearest whole number.
Investor Verification Checklist
- Verify the new CUSIP number (002120 202) for the Company's common stock.
- Confirm the adjusted share count and exercise prices for any held stock options or warrants.
- Review the press release (Exhibit 99.1) for additional details on the rationale for the reverse stock split.
- Check the Company's equity compensation plans for the reduced number of shares reserved for issuance.